Vanguard disaggregates holdings after realignment — Chemed (CHE) shows 0 shares
Rhea-AI Filing Summary
Chemed Corp (CHE) Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Chemed common stock, representing 0% of the class as disclosed in the filing dated 03/13/2026. The filing explains an internal realignment at Vanguard on 01/12/2026 that caused disaggregated reporting by subsidiaries; no beneficial ownership is claimed here.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership and cites an internal realignment.
The amendment states 0 shares and 0% ownership as of the disclosed filing, and it attributes separate reporting to subsidiaries after an internal realignment on 01/12/2026. This is a reporting adjustment rather than a trading disclosure.
Cash‑flow treatment and any prior holdings are not disclosed in the excerpt; subsequent filings or prior schedules would show historical positions if relevant.
FAQ
What does Chemed Corp's Schedule 13G/A from Vanguard (CHE) show?
Does this Schedule 13G/A indicate Vanguard sold Chemed (CHE) shares?
Why does Vanguard report separately after 01/12/2026 in the filing for CHE?
Who signed the Schedule 13G/A amendment for Vanguard regarding CHE?